Irikura Mitsuru, Minami Eri, Ishitsuka Yoichi, Kawase Akihiko, Kondo Yuichi, Irie Tetsumi
Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan.
ISRN Pharmacol. 2012;2012:950603. doi: 10.5402/2012/950603. Epub 2012 May 7.
Background. This study was conducted to investigate the incidence of, and factors associated with, myoclonus-like abnormal movements of Japanese infants following treatment with midazolam in a neonatal intensive care unit (NICU). Methods. We retrospectively investigated abnormal movements and associated risk factors in Japanese infants (less than 1 year old) who received continuous intravenous midazolam treatment in the NICU of the Neonatal Medical Center, Kumamoto City Hospital, Japan, between April 2007 and March 2009. Results. The study included 94 infants who received 119 sessions of midazolam treatment in total. Nine infants (9.6%) developed abnormal movements attributable to midazolam. These nine patients had a significantly lower gestational age at birth, a significantly lower number of weeks after conception at the start of midazolam treatment, and significantly lower body weight compared with patients free of abnormal movements. Logistic regression analysis revealed neonatal asphyxia as a factor associated with an elevated risk of abnormal movements (P = 0.03). Conclusion. The incidence of abnormal movements after midazolam treatment was about 9.6% among the Japanese NICU infants. This result suggests that neonatal asphyxia may be involved in the onset of abnormal movements in infants treated with midazolam.
背景。本研究旨在调查日本新生儿重症监护病房（NICU）中接受咪达唑仑治疗的婴儿发生类肌阵挛异常运动的发生率及相关因素。方法。我们回顾性调查了2007年4月至2009年3月期间在日本熊本市立医院新生儿医学中心NICU接受持续静脉注射咪达唑仑治疗的日本婴儿（小于1岁）的异常运动及相关危险因素。结果。该研究共纳入94名婴儿，他们总共接受了119次咪达唑仑治疗。9名婴儿（9.6%）出现了归因于咪达唑仑的异常运动。与无异常运动的患者相比，这9名患者出生时的胎龄显著更低，开始使用咪达唑仑治疗时的孕龄周数显著更少，体重也显著更低。逻辑回归分析显示新生儿窒息是与异常运动风险升高相关的一个因素（P = 0.03）。结论。在日本NICU婴儿中，咪达唑仑治疗后异常运动的发生率约为9.6%。这一结果表明新生儿窒息可能与接受咪达唑仑治疗的婴儿异常运动的发生有关。
